Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Predictive Oncology Inc. POAI

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Secures $3.074M in Registered Direct Offering

Posted on January 13, 2021 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously disclosed registered direct offering of 3,650,840 shares of its common stock, at a purchase … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Focuses on Multi-Omic Approach to Personalized Treatment Options

Posted on January 12, 2021 by MissionIR

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. The company is building a business around an emerging approach to disease prevention and treatment that … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $3M Registered Direct Offering

Posted on January 8, 2021 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Completes QM CoRE(TM) Integration

Posted on January 6, 2021 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its wholly owned subsidiary Helomics has completed the integration of Quantitative Medicine’s (“QM”) novel active-learning Computational Research Engine … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Engages Investor Relations Firm

Posted on January 5, 2021 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that it has hired an investor relations firm. POAI has chosen Landon Capital to provide investor relations services; the … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Cancels Upcoming Special Meeting of Stockholders

Posted on December 30, 2020 by MissionIR

Predictive Oncology’s (NASDAQ: POAI) Board of Directors has announced that it will cancel the Special Meeting of Stockholders that was scheduled for today. Originally scheduled for Dec. 1, 2020, the meeting was adjourned on that date and rescheduled for Dec. … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Integrates Data, AI to Pave Path for Better Health Outcomes

Posted on December 23, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery, is positioned to play a critical role in the precision oncology industry. The company integrates AI technology … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology (NASDAQ: POAI) Adjourns Special Virtual Meeting; CEO Requesting Shareholder Vote for Critical Tax-Related Proposal

Posted on December 21, 2020 by MissionIR

POAI sent letter to shareholders requesting attendance at virtual Special Meeting on December 30, 2020 Meeting will address reincorporation of POAI in Nevada Reincorporation expected to save POAI approximately $158,000 annually in state taxes Shareholders can vote online or by … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Shines Spotlight on Innovative Media in Exclusive Interview

Posted on December 18, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery, was recently featured in an exclusive audio interview with NetworkNewsWire. During the interview, POAI CEO Carl Schwartz … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology (NASDAQ: POAI) Leverages Precision Medicine Expertise to Support Oncologists, Improve Patient Outcomes

Posted on December 17, 2020 by MissionIR

Precision medicine is emerging approach to disease prevention, treatment that incorporates individual’s distinctive characteristics. New approach allows doctors, researchers to predict more accurately which treatments may work better. Helomics’ database, largest of its kind, is comprised of ovarian, head and … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment